Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer.

NCT04991051 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04991051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04991051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 2, 2021
Completion date
August 15, 2022
Enrollment
605 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer